Home › Acute Lymphoblastic Leukemia › NCT07145411

HPC Offered for PRESERVE Expansion

Who can join

Ages 12 to 80 · All sexes

Inclusion Criteria:

Patients aged 12-80 may be eligible\* to receive bone marrow for transplantation through the Ossium HOPE Program if:

Their treating physician determined they are eligible for allogeneic bone marrow transplant Their treating physician determined that the potential benefit outweighs the potential risks

About the study

Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product

What is being tested

• Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors) (other)

Sponsor: Ossium Health, Inc. · Participants: 10 · Started: Jun 27, 2024

Contact the study team

• Preethi Prasad, Senior Director Clinical Operations · Phone: 415-513-5535

Official record on ClinicalTrials.gov — NCT07145411

Locations in the U.S.

Conditions

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Lymphoma
• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndromes
• Aplastic Anemia
• Sickle Cell Disease

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.